№ files_lp_4_process_3_092054
File format: docx
Character count: 9571
File size: 493 KB
Experimental study on impaction force in jet-based nasal drug delivery devices comparing prototype performance with commercial nasal sprays.
Year:
2026
Region / City:
Lyon, France
Subject:
Nasal drug delivery, impaction force measurement
Document type:
Research article
Institution:
Nemera la Verpillière
Authors:
Laura Berard, Alain Regard
Target audience:
Pharmaceutical researchers, medical device developers
Methodology:
Experimental testing of nasal jet-based prototypes and commercial nasal sprays
Test parameters:
Impaction force, actuation speed, nozzle distance
Comparison:
Marketed nasal saline products, results from C. Guo publication
Key findings:
Jet-based prototypes’ impaction force comparable to commercial products
Device type:
Nasal spray, nasal jet-based prototypes
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2022
Region / city:
Not specified
Topic:
Pediatric treatment for fecal impaction
Document type:
Instruction manual
Author:
Agnieszka Cedro-Sogliani, Heather Lafferty
Target audience:
Pediatric healthcare professionals
Approval date:
12/7/2022
Date of last modification:
Not specified
Year:
2024
Region / City:
United States
Topic:
Medical Appeal Letter
Document Type:
Template
Organization / Institution:
OptiNose, Inc.
Author:
OptiNose, Inc.
Target Audience:
Healthcare providers, medical professionals
Period of Validity:
Indefinite
Approval Date:
05/2024
Date of Changes:
None
Year:
2025
Region / city:
United Kingdom
Topic:
Immunization, Influenza Vaccine
Document Type:
Addendum
Organization / Institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Alex Allen, Greta Hayward
Target Audience:
Health professionals, Immunization Programs
Effective Period:
1 September 2025 - 1 April 2026
Approval Date:
6 August 2025
Modification Date:
23 July 2025
Background:
Live attenuated influenza vaccine nasal spray suspension (Fluenz®) updated formula
Contextual Description:
Addendum to UKHSA PGD v15.0 detailing updates to the influenza vaccine composition and active strains.
Year:
2025
Region / city:
England
Topic:
Influenza Vaccination
Document Type:
Patient Group Direction (PGD)
Authority / institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Jamie Lopez-Bernal, Greta Hayward
Target Audience:
Healthcare practitioners, immunisation staff
Period of validity:
From 1 September 2025 to 1 April 2026
Approval Date:
1 July 2025
Amendment Date:
25 June 2025
Year:
2024
Region / City:
EMEA
Therapeutic Area:
Allergic rhinitis
Document Type:
Product Information
Organization / Institution:
European Medicines Agency
Author:
Not specified
Target Audience:
Healthcare professionals
Validity Period:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2024-2025
Region / City:
Washington State
Topic:
Medical authorization form
Document Type:
Medical Authorization
Organization:
Washington State School for the Blind
Author:
Licensed Health Professional
Target Audience:
Parents/Guardians, School Staff
Effective Period:
07/01/2024 - 08/31/2025
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2022
Note:
Region / city
Topic:
Nasal valve collapse, radiofrequency treatment
Document type:
Medical Procedure Description
Organization / institution:
HERC
Target audience:
Medical professionals
Approval date:
November 2022
Contextual description:
A medical document outlining the procedure code 30469 for repairing nasal valve collapse using low-energy, temperature-controlled radiofrequency treatment, detailing evidence and payer policies.
Authors:
Ruixin Zhou; Carolyn Jordan; Justin Lygrisse; Adrian Raiche
Organization:
Kindeva Drug Delivery, Lexington, KY, USA
Address:
1513 Bull Lea Road, Lexington, KY 40511, USA
Regulatory Authority Referenced:
U.S. Food and Drug Administration (FDA)
Regulatory Document Referenced:
FDA Guidance for Industry: Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products – Chemistry, Manufacturing, and Controls Documentation (July 2002)
Drug Product:
RezenopyTM
Dosage Form:
Nasal spray drug product
Study Type:
Comparative spray characterization and statistical equivalence study
Testing Parameters:
Spray pattern; Droplet size distribution (DV10, DV50, DV90, Span, %Volume < 10 µm); Delivered dose (% of label claim)
Media Compared:
USP Purified Water (USP-PW); Placebo formulation; Drug product formulation
Sample Size:
n=90 per test (30 samples per group)
Statistical Method:
Two-sample equivalence test; 95% confidence interval
Software Used:
Viota® Software; Minitab Statistical Software (version 22.1)
Equipment:
SprayVIEW® measurement system; Spraytec® system
Components Evaluated:
Incoming actuator (pump) lots; Finished combination product
Regulatory Context:
NDA filing; FDA-approved nasal spray product
Year:
2021
Region / City:
Hatfield, United Kingdom
Topic:
Computational Fluid Dynamics, Nasal Delivery Devices, Fluid Mechanics
Document Type:
Research Article
Institution:
University of Hertfordshire, University College London, Bespak
Authors:
Hessam Rasooli Nia, Darragh Murnane, Michael Cook, Adam Gibbons, Sabrina Falloon
Target Audience:
Researchers, Engineers, Pharmaceutical Scientists
Period of Effectiveness:
N/A
Approval Date:
N/A
Modification Date:
N/A
Title:
Supplement to “Broadening the Berlin Definition of ARDS to Patients Receiving High–flow Nasal Oxygen”
Study type:
Observational study
Document type:
Supplement including statistical analysis plan, tables and figures
Study population:
Patients with acute hypoxemic respiratory failure due to COVID–19
Clinical focus:
Acute respiratory distress syndrome according to the Berlin definition
Interventions compared:
High–flow nasal oxygen and invasive ventilation
Severity classification:
Mild, moderate and severe ARDS
Outcomes reported:
ICU discharge, hospital discharge, 28–day mortality, 90–day all–cause mortality
Statistical methods:
Hazard ratios with centre as random effect
Corresponding author:
Fleur–Stefanie L.I.M. van der Ven
Institution:
Department of Intensive Care, Amsterdam University Medical Centers, location ‘AMC’
Country:
The Netherlands
Collaborating group:
PRoAcT–COVID study investigators
Year:
2026
Region / City:
Nottingham, UK
Topic:
Nasal drug delivery, spray drying technology
Document type:
Research paper
Institution:
Upperton Pharma Solutions
Authors:
Lara C. Penn, Shailesh K. Mistry, Richard Johnson
Target Audience:
Pharmaceutical scientists, researchers in drug delivery systems
Date of approval:
2026
Date of amendments:
None
Year:
2026
Region / City:
Not specified
Topic:
Burn Patient Clinical Study
Document Type:
Research Report
Institution:
Not specified
Author:
Not specified
Target Audience:
Medical professionals, researchers
Study Period:
Not specified
Sample Size:
56 participants
Patient Grouping:
Study group and control group
Clinical Intervention:
Inspiratory muscle training
Burn Severity:
Severe (>30% body surface area, 2nd/3rd degree)
Primary Burn Causes:
Fire, hot liquids
Data Analysis Methods:
Descriptive statistics, normality tests, variance tests
Field:
Pharmaceutics and Biopharmaceutics
Topic:
Nasal drug delivery and aerosol particle size assessment
Type of document:
Scientific research article
Authors:
Niklas Baltz; Regina Scherließ
Affiliation:
Department of Pharmaceutics and Biopharmaceutics, Kiel University
Institution:
Kiel University
City:
Kiel
Country:
Germany
Research focus:
Determination of inhalable mass fraction below 10 micron in nasal spray formulations
Studied formulations:
Commercial nasal spray for allergy treatment
Analytical methods discussed:
Impactor analysis; HPLC with UV-Vis detection; comparison with laser diffraction
Tested equipment:
Fast Screening Impactor (FSI); Next Generation Impactor (NGI); reduced NGI (rNGI)
Regulatory context:
EMA and FDA recommendations on nasal product development
Measured parameter:
Mass fraction of droplets or particles less than 10 micron
Application context:
Safety evaluation of intranasal drug administration and potential pulmonary exposure
Related therapeutic area:
Intranasal treatments including therapies targeting the central nervous system
Note:
Year
Organization / Institution:
Centers for Disease Control and Prevention (CDC)
Target Audience:
Research Participants
Lung Function Test Type:
Spirometry
Sample Storage Location:
CDC, Chamblee Campus
Context:
This document provides guidelines for collecting urine samples and performing lung function tests (spirometry) as part of a health study, including sample handling, transportation, and testing protocols.
Year:
2026
Region / city:
Not specified
Topic:
Paediatric respiratory care, bronchiolitis, HFNC therapy
Document Type:
Interview script
Organization / institution:
Not specified
Author:
Not specified
Target Audience:
Clinicians, particularly medical and nursing staff working with infants with bronchiolitis
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2026
Region / City:
Global
Subject:
Emergency treatment of opioid overdose
Document Type:
Pharmaceutical product monograph
Organization / Institution:
OPVEE™ Pharmaceuticals
Author:
OPVEE™ Research and Development Team
Target Audience:
Healthcare professionals and emergency responders
Dosage Form:
Nasal spray
Active Ingredient:
Nalmefene hydrochloride
Indications:
Treatment of known or suspected opioid overdose in patients 12 years and older
Pharmacokinetics:
Nasal administration, onset 2.5–5 minutes, duration ~6 hours above EC50
Safety Considerations:
Pregnancy, lactation, pediatric and geriatric usage, renal and hepatic impairment
Contraindications:
Hypersensitivity to nalmefene or other components
Adverse Effects:
Possible acute withdrawal in opioid-dependent patients, recurrence of respiratory depression